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a b s t r a c t
Statistics play essential roles in evidence-based dentistry (EBD) practice and research. It
ranges widely from formulating scientific questions, designing studies, collecting and
analyzing data to interpreting, reporting, and presenting study findings. Mastering
statistical concepts appears to be an unreachable goal among many dental researchers
in part due to statistical authorities’ limitations of explaining statistical principles to
health researchers without elaborating complex mathematical concepts. This series of 2
articles aim to introduce dental researchers to 9 essential topics in statistics to conduct
EBD with intuitive examples. The part I of the series includes the first 5 topics (1)
statistical graph, (2) how to deal with outliers, (3) p-value and confidence interval, (4)
testing equivalence, and (5) multiplicity adjustment. Part II will follow to cover the
remaining topics including (6) selecting the proper statistical tests, (7) repeated measures
analysis, (8) epidemiological consideration for causal association, and (9) analysis of
agreement.
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1. Introduction
The process of publishing in peer-reviewed journals has
become greatly rigorous in the last decade, researchers are
placed in a continuous battle with armors of journal reviewers.
95% of the approximately 5000 submitted manuscripts every
year to the New England Journal of Medicine are rejected before
they reach the final review by statistical experts who then in
turn reject on average 20% of the manuscripts [1]. A statistical
check list is extremely useful for authors to survive the battle
field of review process and to know where those ‘‘snipers’’ of
queries are shooting at. Many peer-reviewed journals including
Fig. 1 – Comparison of error-bars with statistical
significance.
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Medicine are now publishing useful statistical guidelines [2–4].
This article will introduce some of the essential statistical topics
that have been covered by journal checklists including (1)
statistical graph, (2) how to deal with outliers, (3) p-value and
confidence interval, (4) testing equivalence, (5) multiplicity
adjustment, (6) selecting the proper statistical tests, (7) repeated
measures analysis, (8) non-statistical consideration for causal
association and, and (9) analysis of agreement. Part I of this
series covers the first 5 topics.
2. Statistical graphs and error bars
Error-bars are often used with means. Three different types of
error-bars can be drawn to show measures of data variation
including (1) standard deviation, SD; (2) standard error, SE; and
(3) confidence interval, CI.
Standard deviation (SD) describes variation of ‘‘observed data’’
computed as average distance from each observation to the
sample mean. 95% of observations are thought to fall in a range
of mean  2SD if data are normally distributed.
Standard error (SE) describes accuracy of sample mean computed
as where N indicates sample size.
95% confidence interval (CI) is twice as large as SE. 95%CI =
mean  2SE.
Because graphical interpretation of analytical results
depends on which type of error-bar is used, it is highly
important to understand how each error-bar relates to a
statistical significance. SD describes variation of ‘‘sampled
data’’ which is quantified as the average distance between
each observation to the group mean. For example, SD of the 3
numbers of (5, 6, and 10) is 7 which is computed as average
distance between 5–7, 6–7 and 10–7. SD has a good property
when data are normally distributed, i.e., data are bell-shaped
where the center is located at the middle of its range with
symmetric data variation. SD can be used to describe data
such that 95% of observed data are distributed within
mean  2  SD range. For example, mean age of 50 with SD
of 10 years old translates that 95% of patients’ age range
between 30 and 70 years old. SD is a useful statistical measure
which is used to describe characteristics of observed data.
However, it should not be used when data are presented such
that the SDs imply statistical significance. In figure A, the SD
graphical representation cannot be linked to a p-value for
statistical significance (Fig. 1A). In Fig. 1A the 2 error-barsoverlap; and many people may convert this to the conclusion
that the two means are NOT statistically different. Indeed, the
p-value comparing the 2-group means 0.01 indicating that the
difference is statistically significant.
SE describes variation of sample means; and SE can be
linked to a statistical significance, when error-bar reflects 2
times SE (this is equivalent with 95% confidence interval, 95%
CI). In such graphical plot, non-overlapping error bars often
indicates that the difference in 2 group-means is statistically
significant. In many papers, we see the use of mean  SE in
graphical plots and the interpretation needs extra caution
because the non-overlapping error-bars do not necessarily
indicate statistical significance. In Fig. 1B, the 2 error-bars do
not overlap, although the difference in the 2 group means is
not statistically significant ( p = 0.1). However in Fig. 1C, the
non-overlapping error-bars indicate that the difference was
not statistically significant ( p = 0.1). The mean with error bars
that represent  2  SE (95% CI) need to be presented in order
to link a statistical graph to its corresponding p-value. Thus,
using mean  SE is only confusing, and it should not be used
either in statistical graphs or in result section.
In most papers, errors bars of statistical graphics are poorly
labeled; and without such labeling, error-bars lack their
scientific meaning and they are used merely for ‘‘decorative’’
purpose. This deviates from important statistical principles.
3. Outliers
Data fabrication is a serious crime. We also need to keep in
mind that excluding data in favor of a researcher’s study
hypothesis is just as a serious crime as data fabrication. In
general, excluding outliers is not a good practice, unless there
is a valid reasoning such that outliers are due to a clear data-
error which cannot be corrected. Researchers may worry that
outliers can affect future study funding as they could highly
influence statistical results. This is a misconception, the use of
following methods may considerably reduce the influence of
outliers without excluding any data points.
3.1. Non-parametric method
Use of statistical methods which involve ranks of data instead
of actual values of data can still provide a robust results
regardless of outliers, these methods are called as non-
parametric statistical tests such as Wilcoxon rank-sum test
N=2000 in each group
Mean BP Diﬀerence = 0.5 mmHg
95% CI (-0.8, 1.8) mmHg
N=5 in each group
Mean BP Di ﬀerence = 10 mmHg
95% CI (-15, 35) mmHg
(A)
Mean BP Diﬀerence (mmHg)
(B)
Null




Fig. 2 – Relationship between p-value and confidence
interval.
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mean of C-reactive protein (CRP) for inflammation between 2
groups with each containing 5 patients. Values of CRP is 0.6,
1.2, 2.5, 0.8 and 3 in one group (A) and 0.2, 0.1, 0.5, 0.4 and 15 in
the other group (B). When group mean is compared, we may
think group (B) had a higher mean CRP, as mean of CRP in
group A is 1.62 and 3.24 in group B. Surprisingly, after
excluding the largest CRP value (CRP = 15) in the B group the
mean reduces to 0.3 which reverses the previous conclusion in
comparing the mean of CRP between the two groups. Such
instability of study finding does not occur when ranks are
considered. When we rank the 10 values from the lowest to the
largest, 15 is ranked 10th. When we replace 15 with 2.6, 2.6 is
also ranked 10th. p-Value will remain the same, whether the
outlier has a value of 15 or 2.6, it does not influence the study
result. Non-parametric tests can be used for either skewed and
normally distributed data because they work well with
normally distributed data when sample size is adequately
large (e.g., more than 10 per group). In addition, the use of
nonparametric tests avoid elaborate checking of data dis-
tribution to meet the assumption of parametric tests such as
the t-test.
3.2. Data transformation
Mathematical transformation is a method to reduce bias
caused by outliers, for example, when data are positively
skewed (e.g., data with clustering at lower values and with few
large data-points; cost, biomarker values, time data are often
skewed this way). For such positively skewed data (as opposed
to negatively skewed data where a data-cluster lies at upper
end of data range), logarithmic transformation often improves
normality of data. Two methods of using base-10 or natural-
log provides the same p-value so it does not matter which
transformation is being used. In the previous examples the
CRP values of 0.2, 0.1, 0.5, 0.4 and 15 convert to 0.7, 1, 0.3,
0.4, 1.17 after natural-log transformation, which shrink more
on larger values than smaller one. After applying log
transformation on the data to achieve normality, one may
use parametric test such as t-test for statistical inference.
For most univariable tests, non-parametric method may be
preferred over data transformation, however with regression
analysis, transformation is often warranted. This is due to the
normality of data assumption that is necessary to most
commonly used regression model such as linear regression;
and non-parametric form of regression is often difficult to find
in many statistical softwares.
After considerations of the strategies stated above, if the
researcher still thinks that the ‘‘outlier’’ data points need to be
excluded, the reasoning must be justified to the readers.
Further, a data exclusion considered as outliers must be
followed by a sensitivity analysis showing results before
excluding data points to quantify the degree of influence by
the outliers on study findings.
4. p-Value and confidence interval
p-Value is the probability of observing the difference or a
greater difference when there is in fact no difference. It can beinterpreted as ‘‘the probability of making a misjudgment’’
when difference is claimed based on the observed data.
Thus, the smaller the p-value provides us with the stronger
evidence. Conventionally, we judge statistical significance
when p-value is less than 5%. Then what do we do with p-value
being 5% or greater? We hear in many occasions, people say
‘‘the two-group means are the same’’ or ‘‘the effect of one drug
does not differ from the other thus they are the same’’.
This is a problematic because p-value is a function of (1)
effect of an experimental drug, (2) data-variation, and (3)
sample size. A larger p-value only means that there is
insufficient evidence to claim ‘‘difference’’. Studies with small
sample size often result in such insufficiencies. Lack of
evidence resulting from a large p-value should not be viewed
as ‘‘evidence of equivalence’’. In order to claim statistical
equivalence, we need to conduct a study with a sufficiently
large sample size with equivalent effect of a drug to a
comparison drug. The misuse of p-value for equivalence has in
fact historically helped to claim equivalence on many
approved drugs in market by falsely claiming statistical
equivalence in efficacy with small-size studies.
Confidence interval (CI) is often used with p-value. In fact CI
conveys information which p-value cannot. Point estimate, a
center value of CI indicates observed effect. The width of CI is
computed by 2  SE, where thus increasing sample size (N) will
make CI narrower, and narrower CI makes easier to exclude
the null value from its range. When CI excludes the null value,
we know corresponding p-value is less than 5% indicating
statistical difference. Fig. 2 shows CIs for the estimated mean
difference in blood pressure between a new drug A to a control
drug, and a new drug B to a control group. CI for (A) is much
smaller than CI for (B), yet, they correspond to the same p-
value of 0.4 indicating insufficient evidence to prove the effect
of either of the drugs. Based on CI of (A) one may conclude that
this is an evidence of ‘‘equivalence’’ as the point estimate is
nearly zero and the narrow CI shows good accuracy of the
point estimate With increasing sample size in (A), the CI will
eventually exclude the null value of zero resulting in statistical
significance, however such point estimate no longer would
show a clinically meaningful difference.
On the other hand, with CI of (B), the point estimate for the
mean difference appears to quantify some clinically mean-
ingful value. Yet, either or due to both large variation of data or
small sample size the study is prevented from gaining
accuracy for the estimate resulting in the large CI. Thus
enrolling few more patients in both studies to improve
accuracy of the estimate of mean difference, in which the
Fig. 3 – Interpreting equivalence and superiority using
confidence interval [5].
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not in the study A.
5. Testing equivalence
In general, confidence intervals are used to prove equivalence.
Equivalence may be claimed when both upper and lower
bounds of CI are included in a priori-specified equivalence
margin based on a clinical relevance. Fig. 3 shows 4 different
confidence intervals when we compare mean of blood
pressure between 2 groups. We first need to a priori define a
margin of equivalence where an equivalence is claimed if the
whole range of CI for the mean difference falls in  DmmHg
range around zero. Let’s say D = 5 mmHg in this example.
Example (A), mean difference is 3 indicating a new drug has
3 mmHg lower blood pressure than the control drug. 95% CI for
this mean estimate is (8, 2), we may not claim equivalence
because the lower boundary of 8 exceeds the pre-determined
equivalence margin of 5. Superiority of the experimental
drug is judged if 95% CI does not include the null value, zero in
this case. Based on this, in the scenario (A), neither
equivalence nor superiority may be claimed. On the other
hand, in the scenario (C), 95% CI falls completely in the
equivalence margin and it does not include zero, thus both
equivalence and superiority may be claimed. This provides a
very important principle that statistical significance does not
equate with clinical significance. In this example, equivalence
is claimed on clinical relevance whereas superiority was
judged statistically. p-Value only tells you that the estimated
mean is numerically different from zero, which does not mean
that statistically detected differences are always clinically
meaningful. A researcher should make it a habit of examining
‘‘clinical relevance’’ before referring ‘‘statistical difference’’.
6. Multiplicity adjustment
Conventionally, when p-value is less than 0.05 we use it as an
evidence to claim ‘‘the difference’’. This means that one out of
20 studies is likely to show p-value less than 0.05 when there is
indeed no difference in groups being compared. If there are
100 p-values, 5 out of them are likely to be showing the
difference just by mistake. The magic number ‘‘p < 0.0500 wassuggested by a historic statistician, R.A. Fisher about 90 years
ago which was chosen arbitrarily [6]. In his era, it had taken
hours or days to compute single p-value. Thus it was natural to
think that hypothesis was built based on a careful scientific
reasoning. Technology in the 21st century had brought us an
environment where a millions of p-values can be computed in
few hours, or even in few minutes, which has brought us a
huge problem of over-detection of statistical significance (i.e.,
false discovery).
Over-detection of statistical significance (multiplicity)
often occurs when many statistical testings are performed.
Most commonly referred example may come from an analysis
of comparing many groups. In this case, a researcher may
want to perform many pairwise comparisons, for example,
comparing group A vs. group B, group B vs. group C, and group
A vs. group C and so on. Each pairwise comparison computes a
single p-value, thus when 4 groups are compared, 6 p-values
may be computed. As it was stated previously, p-value is
interpreted as the probability of falsely claiming a difference
when there is no difference, and conventionally we are
allowed to make this false judgment up to 5% with each
comparison. This is similar to buying lottery tickets and
chance of winning. If someone buys a lottery, and each lottery
has a winning probability of 5%; the more lotteries he buys, his
chance of winning at least with one lottery increases. By the
same reasoning, when many statistical tests are performed,
the opportunity to discover a difference by chance increases.
This is called ‘‘inflation of type I error’’ in statistical technical
terms. In order to reduce this type I error rate, each statistical
test should use more rigorous significance level to claim
difference. Bonferroni adjustment is the most commonly used
method of multiplicity adjustment. In Bonferroni method, we
typically divide significance level by the number of pairwise
comparisons being performed, thus with 6 pairwise compar-
isons, we may not claim statistical significance unless p-value
is less than 0.0083.
The concept of multiplicity has gained familiarity among
researchers due to the continuing effort by journal reviewers
advocating the use of rigorous significance level with multiple
comparisons. Many statisticians question if such adjustment
is really necessary. In the literature, multiplicity adjustment is
most often performed in studies analyses involving more than
2 comparison groups. However, there are many other
occasions as shown in the following where multiplicity can
occur [7].
 Multiple outcomes
 Multiple comparison groups
 Multiple comparison groups due to differential dosing
 Multiple independent variables in a regression
 Multiple datasets for a single hypothesis




 Analysis at multiple time points
Thus, if adjustment is warranted every time we encounter
one or more of the situation listed above, claiming statistical
significance becomes very difficult. With the multiplicity
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difference? The error of not being able to detect the difference
when there is a difference, is called type II error. Don’t we need
to worry about inflation of type II error? Do we need to adjust
for multiplicity systematically? If the answer is no, what are
the appropriate situations? In fact, whether we adjust for
multiplicity has invited a large debate in last few decades. A
world respected epidemiologist, Kenneth Rothman quoted
that ‘‘No adjustments are needed for multiple comparisons.
Unfortunately, reducing the type I error for null associations
increases the type II error for those associations that are not
null’’ [8]. A renowned British statistician in drug trials, Stephen
Senn stated that ‘‘It can be claimed that, if all tests conducted
are reported not only significant but non-significant results,
then there should be no problem’’ (Note that even on this
viewpoint, selectively reporting those tests which are sig-
nificant, whilst ignoring the others, does cause a bias, however
if all tests which are to be performed are reported with the
order stated in the trial protocol) [9]. He added ‘‘In general, the
probability of making a type I error depends upon correlations
between the outcomes. The Bonferroni correction is rather
pessimistic and will be conservative when it is applied to
clinical outcomes which are often correlated’’.
I have reviewed many papers where authors chose not to
do adjustment; and I was not convinced that it was the best
approach and suggested to the authors to consider at least
some protection against multiplicity. The basis of my rationale
is further illustrated by a quote of statisticians in the National
Heart, Lung and Blood Institutes: ‘‘On the other hand, one
cannot help feeling uneasy when one of many comparisons
made reaches statistical significance. This has led some
statisticians to be very conservative, and almost always adjust
for multiple comparisons. The optimal course is probably
somewhere between these two extremes’’.
Some says multiplicity adjustment is necessary, and others
say not so. There is no clear guideline suggesting when it
needs to be done, and when it is not. As long as we continue to
practice statistics with p-values, it is difficult to remove our
concern from multiplicity. Meanwhile, there have been new
approach of statistics such as Bayesian and Likelihood ratio
methods, these methods avoid the use of p-values and
emphasize the importance of estimation rather than hypoth-
esis tests. The long debate on whether we need to consider
multiplicity adjustment may be ending with the increasing
use these statistical methods.
Over-detection of statistical significance takes also place
when a researcher conducts un-specified analyses without a
priori planned out hypotheses, and reports findings only if they
are statistically significant. These unguided analyses are
infamously referred to as ‘‘fishing’’, ‘‘cherry picking’’ and
‘‘data-dredging’’. We passionately decry such practice because
the analysis loses reproducibility due to results that are based on
extensive data mining. If the result of a study is not reproducible,
how can we call such findings have scientific basis? If R.A. Fisher
lived in this society of computerization where millions of p-
values are computed in a matter of seconds, he would not come
up with the magic number of 0.05. In the statistical guideline by
British Dental Journal, multiplicity issue is presented as it is
more problematic with studies lacking a priori-determined
hypotheses. They state that multiplicity concerns is less of anissue in a study with few a priori-determined hypotheses.
Otherwise, multiplicity adjustment is necessary and the results
should be presented only as ‘‘exploratory’’ and avoid presenting
them as ‘‘confirmatory’’ evidence.
I have found practical advices in a text book of Biostatistics
by Bernard Rosner which I refer to students in the advanced
biostatistics course that I teach. Rosner states ‘‘Multiple-
comparisons procedures should be used if there are many
groups and not all comparisons between individual groups
have been planned in advance. However if there are relatively
few groups which have been planned in advance, and the
global test such as ANOVA test for equivalence of means is
significant then adjusting p-value for multiple-comparisons is
not so important [10]. But researchers need to keep in mind
that consideration is yet ‘‘case-by-case’’.
European Medicines Agency (EMEA) suggests that the
following scenarios for which multiplicity may not be
considered [7]:
 Two or more primary outcome variables are ranked
according to clinical relevance. However, no confirmatory
claims can be based on variables that have a rank lower than
or equal to that variable whose null hypothesis was the first
that could not be rejected (e.g., in order to claim outcome 2 is
significant, outcome 1 must be significant).
 Two or more primary outcome variables are needed to
describe clinically relevant treatment benefits.
 One analysis is stated primary, and other outcome is stated
as a sensitivity analysis.
 Multiple comparison groups due to deferential dosing of a
drug – when the purpose of the analysis is to demonstrate
overall positive correlation of the clinical effect with
increasing dose, it is not necessary to perform multiplicity
adjustment after statistical significance is detected with a
global test such as a linear trend test.
7. Conclusions
There are many points being mentioned in this paper that
could be overwhelming for researchers. These take-home
points will summarize the important concepts:
Statistical graphs and error bars
 Clearly label error bars with SD, SE or 95% CI.
 SD is a common choice for descriptive analysis typically given
in tables showing patients’ baseline characteristics, and 95%
CI should be used when statistical inference is being made.
 Do not use SE anywhere in your paper.
Outliers
 Avoid deleting observations unless you have a clear data-
error.
 Any deletion of outliers must be reported with the number
being deleted.
 Consider using statistical methods which are less influenced
by outliers including data-transformation and the use of
non-parametric tests.
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 p-Value is the probability of mistakenly claiming difference.
 Confidence interval (CI) conveys more information than p-
value, thus it should be used along with p-value.
Proving equivalence
 p > 0.05 does not indicate ‘‘equivalence’’. Do not use p-value
for testing equivalence.
 Equivalence can be judged if the lower and upper
bounds of CI is inside of a priori determined equivalence
margin.
Multiplicity adjustment
 Over-detection of statistical significance can be caused by
performing many statistical tests.
 Adjustment of significance level may be necessary to avoid
such over-detection but this is yet under a debate.
 A careful pre-planning of analytical strategy is always
necessary to avoid unnecessary analyses to reduce chance
of over-detection.
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